Roche, Lilly tag-team Alzheimer’s blood test

Today's Big News

Mar 22, 2023

After appeals loss, Johnson & Johnson will take Texas two-step case to the US Supreme Court 


VistaGen finds open-label success with social anxiety nasal spray, but Palisade pivotal trial remains iced


Roche, Eli Lilly team up on Alzheimer’s biomarker blood test


AbbVie's blockbuster-to-be Parkinson's combo hits a wall as FDA questions delivery pump


Astellas enjoys warm glow of success as antibody against hot cancer target hits again in phase 3


Medtronic adds Nvidia's AI to colorectal polyp-spotting software

 

Featured

After appeals loss, Johnson & Johnson will take Texas two-step case to the US Supreme Court

After an unsuccessful bid to get its appeal reheard in the Third Circuit Court on Wednesday, Johnson & Johnson said it will make one last appeal to the U.S. Supreme Court to legitimize its strategy to funnel more than 38,000 talc lawsuits into a company it created with the intent to declare it bankrupt.
 

Top Stories

VistaGen finds open-label success with social anxiety nasal spray, but PALISADE pivotal trial remains iced

VistaGen's social anxiety nasal spray passed an open-label phase 3 test, showing it was safe and effective. The company said treated patients also showed improvement in a measurement of social anxiety.

Roche, Eli Lilly team up on Alzheimer's biomarker blood test

As Eli Lilly inches ever closer to the finish line in its yearslong mission to bring an Alzheimer’s disease drug to the market, the company has picked up a side quest.

AbbVie's blockbuster-to-be Parkinson's combo hits a wall as FDA questions delivery pump

In what’s expected to be one of AbbVie’s “biggest new product launches” in the coming years, the company has hit a snag. The FDA rejected AbbVie’s Parkinson’s disease combo therapy over questions about its delivery pump.

Astellas enjoys warm glow of success as antibody against hot cancer target hits again in phase 3

Astellas Pharma’s zolbetuximab has gone two for two, chalking up a second phase 3 win to cement its status as the front-runner in the race to deliver a drug against one of the hottest targets in cancer today.

Medtronic adds Nvidia's AI to colorectal polyp-spotting software

Medtronic and Nvidia announced a partnership this week that will see them attempt to build out an entire ecosystem of AI tools for diagnosis and other healthcare uses, using the GI Genius colonoscopy AI as a jumping-off point.

Flare fires up with $123M series B to target transcription factors with 3 Big Pharmas in tow

Things are heating up at Flare Therapeutics, with big names like Pfizer, Eli Lilly and Novartis adding fuel to the biotech’s fire in a new $123 million financing round.

US again spurns march-in campaign to slash cost of Pfizer, Astellas' Xtandi

The National Institutes of Health (NIH) rejected a petition to exercise so-called march-in authority around Pfizer and Astellas' Xtandi. The same fate befell a similar petition back in 2016 and comes after a trio of U.S. Senators last year pressed Department of Health and Human Services Secretary Xavier Becerra to move forward with the campaign.

Cognito beams up $73M for study of light-and-sound neuromod therapy to treat Alzheimer's

Riding high on early clinical trial results showing that its neuromodulation headset can improve memory and cognition and slow the deterioration of white matter in the brains of people with Alzheimer’s disease, Cognito Therapeutics has now secured a flurry of funding to delve even deeper into the technology.

GSK, eyeing new blockbuster market, taps Magic Johnson to raise RSV awareness ahead of Pfizer faceoff

GSK has teamed up with Earvin “Magic” Johnson to “Sideline RSV.” Working with the former basketball star and public health advocate, GSK is raising awareness of the risks respiratory syncytial virus (RSV) poses to older adults—and laying the groundwork for its upcoming vaccine launch in the process.

Biohaven tacks on brain disorder med to its pipeline, lining up $970M for ex-China rights to Highlightll drug

Biohaven is using business development to once again bolster its pipeline, this time tacking on a brain-penetrating treatment for neuroinflammatory diseases slated to hit the clinic within a year. Biohaven has signed a $970 million agreement with Highlightll Pharma for ex-China rights to the drug.

Novartis, after prior deal with NHS England, scraps large-scale Leqvio trial

After Novartis in 2020 struck a partnership with England's National Health Service to study cholesterol-lowering drug Leqvio as a primary prevention med in patients with atherosclerotic cardiovascular disease, the company is changing course.

#FierceMadness 2023: After AbbVie, Pfizer lose in the opening round, your Sweet 16 bracket awaits

If it’s March, it must be #FierceMadness, Fierce Pharma Marketing’s annual take on the March Madness NCAA basketball tournament and bracket mania—with a pharma twist.
 
Fierce podcasts

Don't miss an episode

'The Top Line': The SVB failure, plus this week's headlines

This week on "The Top Line," we discuss the SVB failure, what to expect next and what it all meant for the biotech industry. We also cover Pfizer's big acquisition, insulin prices and more of this week's top headlines.

 

Resources

Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.
Executive Summary

Optimizing drug discovery in a fast-moving market

Read about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines.
Whitepaper

Answering your specific questions about mRNA/saRNA manufacturing

Have you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here.
Whitepaper

Proven Pharmaceutical Go-To-Market Model

Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success.

Whitepaper

Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Research

Step-wise strategy to address process characterization and late phase development

Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development.

Case Study

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Research

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
 

Industry Events

 

Upcoming Fierce Events

20-22
Mar
West Palm Beach, FL
3-4
Apr
San Diego, CA
1-3
May
May 1-3, 2023 | Jersey City, NJ
23
May
Free Virtual Event
12-14
Jun
San Diego, CA

View all events